MaxCyte, Inc.

NasdaqGS MXCT

MaxCyte, Inc. Price to Sales Ratio (P/S) on February 06, 2025: 10.36

MaxCyte, Inc. Price to Sales Ratio (P/S) is 10.36 on February 06, 2025, a -17.08% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

MaxCyte, Inc. 52-week high Price to Sales Ratio (P/S) is 12.52 on February 12, 2024, which is 20.85% above the current Price to Sales Ratio (P/S).
MaxCyte, Inc. 52-week low Price to Sales Ratio (P/S) is 7.47 on November 18, 2024, which is -27.90% below the current Price to Sales Ratio (P/S).
MaxCyte, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 9.91.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: MXCT

MaxCyte, Inc.

CEO	Mr. Maher Masoud
IPO Date	July 30, 2021
Location	United States
Headquarters	9713 Key West Avenue
Employees	143
Sector	Healthcare
Industries Biotechnology 3D Printing

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key trends

Past 5 years